A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237
 in patients with chronic obstructive pulmonary disease (COPD).
Inclusion Criteria:

 -  Diagnosed with COPD, with symptoms of cough and chronic sputum production and/or
 dyspnea.

 -  Post-bronchodilator FEV1 at no more than 65% and at least 30% of the predicted normal
 value.

 -  Pre-bronchodilator FEV1/FVC ratio of less than 70%.

 -  Current or ex-smokers with a smoking history of at least 10 pack years.

 Exclusion Criteria:

 -  History of asthma, atopy or allergic rhinitis.

 -  Other serious respiratory or other medical conditions which may interfere with the
 outcome of the study.